Actuate Therapeutics, Inc. - Common stock (ACTU)
7.2200
+0.3100 (4.49%)
NASDAQ · Last Trade: Apr 3rd, 7:53 PM EDT
Detailed Quote
| Previous Close | 6.910 |
|---|---|
| Open | 6.590 |
| Bid | 7.050 |
| Ask | 7.230 |
| Day's Range | 6.350 - 7.310 |
| 52 Week Range | 5.510 - 11.73 |
| Volume | 59,372 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 35,774 |
Chart
About Actuate Therapeutics, Inc. - Common stock (ACTU)
Actuate Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in the treatment of various diseases, with a particular emphasis on precision medicine approaches. The company's research and development efforts are directed toward drug candidates that target specific biological pathways, aiming to improve patient outcomes and enhance the quality of life for individuals suffering from complex health conditions. Actuate's commitment to advancing scientific understanding in therapeutic areas positions it as a key player in the biopharmaceutical industry, with the goal of bringing transformative treatments to market. Read More
News & Press Releases
Via Benzinga · January 28, 2025
Via Benzinga · December 13, 2024
Pheton Holdings and Powell Max opened for trading on Thursday at $3.76 and $4.30, respectively. While the number of initial public offerings has rebounded from 2023, IPOs remain well below pre-pandemic levels.
Via Talk Markets · September 8, 2024
Actuate Therapeutics opened on Aug. 13 at $9.88. The biopharmaceutical company had priced its initial public offering of 2.8 million shares at a price of $8.00 per share.
Via Talk Markets · August 18, 2024
InvestorNewsBreaks – Actuate Therapeutics, Inc. (NASDAQ: ACTU) Closes on $22.4M Initial Public Offering
Actuate Therapeutics (NASDAQ: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, recently announced the closing of its previously announced initial offering. The offering comprised 2,800,000 shares of the company’s common stock at a price of $8.00 per unit to the public, raising a total of $22,400,000 in gross proceeds before deductions. In addition, the company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares, representing 15% of the shares sold in the offering, solely to cover over-allotments, if any, at the initial public offering price, less the underwriting discounts and commissions. The company’s shares began trading on August 13, 2024, on the Nasdaq Global Market under the ticker symbol ACTU.
Via Investor Brand Network · August 15, 2024